Current compound coverage of the kinome.

Publicly available kinase inhibitors have been analyzed in detail. Nearly 19000 inhibitors have been identified with activity against 266 different kinases. Thus, about half of the human kinome is currently covered with active small molecules. The distribution of inhibitors across the kinome is uneven. Most available kinase inhibitors are likely to be type I inhibitors. By contrast, type II inhibitors are rare but usually have high potency. Kinase inhibitors generally display high scaffold diversity. Activity cliffs with an at least 100-fold difference in potency are only found for inhibitors of 106 kinases, which is partly due to only small numbers of compounds available for many kinases, in addition to scaffold diversity. Moreover, kinase inhibitors are less promiscuous than often thought. More than 70% of available inhibitors are only annotated with a single kinase activity, and only ∼1% of the inhibitors are active against five or more kinases.

[1]  G. Bemis,et al.  The properties of known drugs. 1. Molecular frameworks. , 1996, Journal of medicinal chemistry.

[2]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[3]  Mark Johnson,et al.  Using Molecular Equivalence Numbers To Visually Explore Structural Features that Distinguish Chemical Libraries , 2002, J. Chem. Inf. Comput. Sci..

[4]  J. Warmus,et al.  Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition , 2004, Nature Structural &Molecular Biology.

[5]  L. Wodicka,et al.  A small molecule–kinase interaction map for clinical kinase inhibitors , 2005, Nature Biotechnology.

[6]  J. Mestan,et al.  Allosteric inhibitors of Bcr-abl–dependent cell proliferation , 2006, Nature chemical biology.

[7]  N. Gray,et al.  Rational design of inhibitors that bind to inactive kinase conformations , 2006, Nature chemical biology.

[8]  Mindy I. Davis,et al.  A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.

[9]  A. Cheng,et al.  Analysis of kinase inhibitor selectivity using a thermodynamics-based partition index. , 2010, Journal of medicinal chemistry.

[10]  R. Ward,et al.  Kinase Drug Discovery , 2011 .

[11]  P. Hajduk,et al.  Navigating the kinome. , 2011, Nature chemical biology.

[12]  K. Nguyen,et al.  Discovery and optimization of a series of 3-(3-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amines: orally bioavailable, selective, and potent ATP-independent Akt inhibitors. , 2012, Journal of medicinal chemistry.

[13]  Jürgen Bajorath,et al.  Extending the Activity Cliff Concept: Structural Categorization of Activity Cliffs and Systematic Identification of Different Types of Cliffs in the ChEMBL Database , 2012, J. Chem. Inf. Model..

[14]  Jürgen Bajorath,et al.  Growth of Ligand-Target Interaction Data in ChEMBL Is Associated with Increasing and Activity Measurement-Dependent Compound Promiscuity , 2012, J. Chem. Inf. Model..

[15]  Jürgen Bajorath,et al.  MMP-Cliffs: Systematic Identification of Activity Cliffs on the Basis of Matched Molecular Pairs , 2012, J. Chem. Inf. Model..

[16]  John P. Overington,et al.  ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..

[17]  Jürgen Bajorath,et al.  High-resolution view of compound promiscuity , 2013, F1000Research.

[18]  Alexander Levitzki,et al.  Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance. , 2013, Annual review of pharmacology and toxicology.

[19]  Eddine Saiah,et al.  Approaches to discover non-ATP site kinase inhibitors , 2013 .

[20]  Jürgen Bajorath,et al.  New frontiers in kinases: second generation inhibitors. , 2014, Journal of medicinal chemistry.

[21]  I. D. de Esch,et al.  KLIFS: a knowledge-based structural database to navigate kinase-ligand interaction space. , 2014, Journal of medicinal chemistry.

[22]  George Papadatos,et al.  The ChEMBL bioactivity database: an update , 2013, Nucleic Acids Res..

[23]  S. Knapp,et al.  Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery? , 2014, ACS chemical biology.

[24]  Jürgen Bajorath,et al.  Recent progress in understanding activity cliffs and their utility in medicinal chemistry. , 2014, Journal of medicinal chemistry.